Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs

通过风险分层社区参与计划验证用于早期检测胰腺癌的新型成像和分子测试

基本信息

  • 批准号:
    10640704
  • 负责人:
  • 金额:
    $ 76.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-15 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT To diagnose pancreatic ductal adenocarcinoma (PDAC) in its precursor or early stages, novel screening tools must apply liquid biomarkers with localization using novel imaging strategies in high-risk populations. The OHSU PCDC Research Unit proposes three aims highlighting its multidisciplinary strengths in cancer biology, imaging, and implementation science. The overarching theme of the proposed research focuses on sensitivity, feasibility, and patient acceptability. Our sensitive blood-based screening test can be applied with minimal quantities of blood and is easily modifiable based on further discoveries. If positive, this would prompt application of a feasible, non-contrast, and robust magnetic resonance imaging (MRI) protocol that augments MRI and magnetic resonance chlangiopancreatography (MRCP) of the pancreas with quantitatively rigorous MR Fingerprinting (MRF). MRF can simultaneously quantify parameters that are associated with fibrosis and inflammation (T1, T2, and T1p). We hypothesize that these parameters are upregulated in high-grade dysplasia (e.g., high-risk intraductal papillary mucinous neoplasms (IPMNs) and grade 2-3 pancreatic intraepithelial neoplasia (PanIN)) and early-stage pancreatic ductal adenocarcinoma (PDAC). Further, quantitative MRI will reduce the high interobserver variability of MR interpretation and requirement for time consuming and technically complex MR protocols that can be challenging to implement outside of pancreas referral centers. If successful, MRF may obviate the need for Gadolinium based contrast agents in screening populations undergoing frequent MRI and MRCP. Finally, we will increase enrollment of high-risk individuals into PCDC Signature Cohorts, through leveraging an existing large, statewide cohort, Healthy Oregon Project. Further, we will work collaboratively with our Community Outreach, Research & Engagement team to understand and address barriers to engagement in PDAC surveillance among members of minoritized communities, particularly those who suffer disproportionally from PDAC. These efforts will ensure participation among underrepresented populations who are least likely to take part in cancer screening while contributing to the consortium mission of expanding PCDC Signature Cohorts. The OHSU Research Unit is prepared to meaningfully collaborate with the PCDC Consortium by sharing existing resources from the Oregon Pancreas Tissue Registry (> 3,700 patients enrolled), OHSU PRECEDE consortium subjects (> 100 high-risk individuals enrolled to date) and potential expansion to other PRECEDE centers, and the OHSU High Risk Pancreatic Cancer Screening clinic (> 750 unique patients who have completed at least one screening test). In addition, our team includes experts in implementation science who have designed and activated the Healthy Oregon Project, an app-based platform that allows at-home acquisition of genetic data through mail-in kits and population-based interaction to find and interact with high-risk individuals.
项目摘要/摘要 诊断胰腺导管腺癌(PDAC)的先兆或早期,新的筛查工具 必须在高危人群中应用液体生物标记物,并使用新的成像策略进行定位。OHSU PCDC研究单位提出了三个目标,以突出其在癌症生物学、成像、 和实施学。拟议研究的主要主题集中在敏感性、可行性、 以及患者的可接受性。我们敏感的基于血液的筛查测试可以应用于最少量的 血液,并且很容易根据进一步的发现进行修改。如果是肯定,这将促使应用一种可行的、 无对比度和强大的磁共振成像(MRI)协议,增强了MRI和 胰腺磁共振胆胰管成像(MRCP)的定量严谨MR指纹分析 (MRF)。MRF可以同时量化与纤维化和炎症相关的参数(T1,T2, 和T1p)。我们假设这些参数在高级别异型增生(例如,高危)中上调 导管内乳头状黏液性肿瘤(IPMN)和2-3级胰腺上皮内肿瘤(PanIN)) 早期胰腺导管腺癌(PDAC)。此外,定量核磁共振将降低高 MR解释的观察者间变异性和对耗时且技术复杂的MR的要求 在胰腺转诊中心外实施可能具有挑战性的方案。如果成功,MRF可能会 在筛查频繁接受MRI和MRI检查的人群中,不再需要基于Gd的造影剂 MRCP。最后,我们将通过以下方式增加高危个人加入PCDC签名队列 利用现有的大型、全州范围的健康俄勒冈项目。此外,我们将与 我们的社区外展、研究和参与团队了解并解决参与的障碍 对小型化社区成员,特别是那些遭受不成比例痛苦的人进行PDAC监测 来自PDAC。这些努力将确保在代表人数不足的人群中参与,他们最不可能 参与癌症筛查,同时为扩大PCDC签名的财团使命做出贡献 一群人。 OHSU研究组准备通过分享与PCDC联盟进行有意义的合作 俄勒冈州胰腺组织注册中心(登记了3,700名患者)的现有资源,OHSU在 联盟受试者(到目前为止已登记了100名高危个体)和潜在的扩展到其他人之前 中心和OHSU高风险胰腺癌筛查诊所(>750名具有 至少完成一次筛查测试)。此外,我们的团队还包括实施科学方面的专家 我设计并激活了健康俄勒冈项目,这是一个基于应用程序的平台,允许在家中进行收购 通过邮寄工具包和基于人群的互动来获取遗传数据,以发现高危个体并与其互动。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gregory A Cote其他文献

Gregory A Cote的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gregory A Cote', 18)}}的其他基金

SpHincterotomy for Acute Recurrent Pancreatitis
乳头括约肌切开术治疗急性复发性胰腺炎
  • 批准号:
    10469267
  • 财政年份:
    2021
  • 资助金额:
    $ 76.69万
  • 项目类别:
SpHincterotomy for Acute Recurrent Pancreatitis
乳头括约肌切开术治疗急性复发性胰腺炎
  • 批准号:
    10480901
  • 财政年份:
    2021
  • 资助金额:
    $ 76.69万
  • 项目类别:
SpHincterotomy for Acute Recurrent Pancreatitis
乳头括约肌切开术治疗急性复发性胰腺炎
  • 批准号:
    10019527
  • 财政年份:
    2018
  • 资助金额:
    $ 76.69万
  • 项目类别:
SpHincterotomy for Acute Recurrent Pancreatitis
乳头括约肌切开术治疗急性复发性胰腺炎
  • 批准号:
    9495849
  • 财政年份:
    2018
  • 资助金额:
    $ 76.69万
  • 项目类别:
Minor Endoscopic Sphincterotomy for Recurrent Acute Pancreatitis with Pancreas Divisum
小内镜下乳头括约肌切开术治疗复发性急性胰腺炎伴胰分裂
  • 批准号:
    9264121
  • 财政年份:
    2016
  • 资助金额:
    $ 76.69万
  • 项目类别:
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures
优化 ERCP 在评估不确定性胆管狭窄中的作用
  • 批准号:
    8434842
  • 财政年份:
    2012
  • 资助金额:
    $ 76.69万
  • 项目类别:
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures
优化 ERCP 在评估不确定性胆管狭窄中的作用
  • 批准号:
    8817282
  • 财政年份:
    2012
  • 资助金额:
    $ 76.69万
  • 项目类别:
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures
优化 ERCP 在评估不确定性胆管狭窄中的作用
  • 批准号:
    8638001
  • 财政年份:
    2012
  • 资助金额:
    $ 76.69万
  • 项目类别:
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures
优化 ERCP 在评估不确定性胆管狭窄中的作用
  • 批准号:
    8996766
  • 财政年份:
    2012
  • 资助金额:
    $ 76.69万
  • 项目类别:
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures
优化 ERCP 在评估不确定性胆管狭窄中的作用
  • 批准号:
    8280031
  • 财政年份:
    2012
  • 资助金额:
    $ 76.69万
  • 项目类别:

相似海外基金

Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
  • 批准号:
    10635325
  • 财政年份:
    2023
  • 资助金额:
    $ 76.69万
  • 项目类别:
In vivo Identification of Pre-Atrophic Brain Neurodegeneration in Prodromal Alzheimer Disease with Quantitative Gradient Recalled Echo MRI
利用定量梯度回忆回波 MRI 体内鉴定阿尔茨海默病前驱期的萎缩前脑神经变性
  • 批准号:
    10448152
  • 财政年份:
    2022
  • 资助金额:
    $ 76.69万
  • 项目类别:
The Development and Rescue of an Atrophic Nonunion Model
萎缩性骨不连模型的开发和挽救
  • 批准号:
    10007577
  • 财政年份:
    2019
  • 资助金额:
    $ 76.69万
  • 项目类别:
The Development and Rescue of an Atrophic Nonunion Model
萎缩性骨不连模型的开发和挽救
  • 批准号:
    10242918
  • 财政年份:
    2019
  • 资助金额:
    $ 76.69万
  • 项目类别:
Analysis of the role of AMPK in the retina for the development of a novel treatment for atrophic age-related macular degeneration
分析 AMPK 在视网膜中的作用,以开发治疗萎缩性年龄相关性黄斑变性的新方法
  • 批准号:
    18K09457
  • 财政年份:
    2018
  • 资助金额:
    $ 76.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regeneration of atrophic salivary glands by reconstructing tissue macrophages using amniotic fluid-derived cells
利用羊水来源的细胞重建组织巨噬细胞来再生萎缩的唾液腺
  • 批准号:
    19K21370
  • 财政年份:
    2018
  • 资助金额:
    $ 76.69万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
The study to detect early-stage pancreatic cancer based on the data from molecular biology about the atrophic acinar cell surrounding carcinoma in situ.
该研究基于原位癌周围萎缩性腺泡细胞的分子生物学数据来检测早期胰腺癌。
  • 批准号:
    18K07897
  • 财政年份:
    2018
  • 资助金额:
    $ 76.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multiple control and visualization of self-somatic- stem cells for atrophic jaw bone augmentation
用于萎缩颌骨增量的自体干细胞的多重控制和可视化
  • 批准号:
    17H04394
  • 财政年份:
    2017
  • 资助金额:
    $ 76.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Delivery of concentrated peripheral blood derived EPCs and functional miRNAs for atrophic salivary gland regeneration
输送浓缩的外周血来源的 EPC 和功能性 miRNA 以促进萎缩唾液腺再生
  • 批准号:
    17K17272
  • 财政年份:
    2017
  • 资助金额:
    $ 76.69万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of novel oligonucleotide therapeutics using functional liposomes for atrophic muscular disorder
使用功能性脂质体开发治疗萎缩性肌肉疾病的新型寡核苷酸疗法
  • 批准号:
    16K20646
  • 财政年份:
    2016
  • 资助金额:
    $ 76.69万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了